Impact of Acotiamide Affects Meal-related Symptoms and Lower Abdominal Symptoms in Functional Dyspepsia in Japan

Seiji Futagami

doi:10.15344/2393-8498/2014/109

Abstract

Background: To clarify whether acotiamide improve postprandial distress symptoms and lower abdominal symptoms through affecting hypothalamic-pituitary-adrenal (HPA) axis in FD patients. Methods: We used Rome III criteria to evaluate upper and lower abdominal symptoms. Twenty-five functional dyspepsia (FD) patients were treated with acotiamide (300mg/day) for 4 weeks. Anxiety was evaluated using STAI-state/-trait. We measured ACTH and cortisol levels in FD patients. Results: Acotiamide treatment significantly (p=0.007, p=0.003) improved postprandial fullness and early satiety in 4 weeks treatment in FD patients compared to those in pretreatment. In contrast, acotiamide treatment improved lower abdominal symptoms, while insignificantly. Acotiamide did not also affect anxiety using STAI-state/-trait. Acotiamide treatment for 4 weeks did not affect ACTH and cortisol levels in FD patients. Conclusions: Further studies will be needed to clarify how acotiamide improve clinical symptoms in FD patients.

Highlights

Material and MethodsAccording to the Rome III criteria, the major symptoms of functional dyspepsia (FD) consist of bothersome postprandial fullness, early satiety, epigastralgia, and epigastric burning [1]
There is no available data whether acotiamide affect FD symptoms and lower gastrointestinal (GI) tract symptoms
In this study, we have first investigated whether acotiamide treatment is more effective for constipation score in FD patients

Summary

Introduction

According to the Rome III criteria, the major symptoms of FD consist of bothersome postprandial fullness, early satiety, epigastralgia, and epigastric burning [1]. Functional dyspepsia is treated by two major categories of drugs; acid inhibitors such as H2-receptor antagonists and proton pump inhibitors (PPIs), and prokinetic drugs which accelerate disturbed GI motility with modifying altered visceral sensitivity. To clarify whether acotiamide improve postprandial distress symptoms and lower abdominal symptoms through affecting hypothalamic-pituitary-adrenal (HPA) axis in FD patients. Methods: We used Rome III criteria to evaluate upper and lower abdominal symptoms. Results: Acotiamide treatment significantly (p=0.007, p=0.003) improved postprandial fullness and early satiety in 4 weeks treatment in FD patients compared to those in pretreatment. Acotiamide treatment improved lower abdominal symptoms, while insignificantly. Acotiamide did not affect anxiety using STAI-state/-trait. Acotiamide treatment for 4 weeks did not affect ACTH and cortisol levels in FD patients. Conclusion: Further studies will be needed to clarify how acotiamide improve clinical symptoms in FD patients

Objectives

Results

Discussion

Conclusion